ES2515715T3 - Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico - Google Patents
Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico Download PDFInfo
- Publication number
- ES2515715T3 ES2515715T3 ES11788223.3T ES11788223T ES2515715T3 ES 2515715 T3 ES2515715 T3 ES 2515715T3 ES 11788223 T ES11788223 T ES 11788223T ES 2515715 T3 ES2515715 T3 ES 2515715T3
- Authority
- ES
- Spain
- Prior art keywords
- rsd
- usp
- time
- pancreolipase
- microcrystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición que contiene al menos una enzima digestiva y al menos un portador en la que: a) la cantidad total de enzimas digestivas en la composición es entre aproximadamente 4 y aproximadamente 20% en peso, donde el portador se elige del grupo que consiste en polioles, azúcares, alcoholes de azúcar, celulosa, sales de fosfato de calcio, aminoácidos y sus mezclas; y al menos un portador de la composición tiene un tamaño de partícula mayor de 100 μm.
Description
E11788223
13-10-2014
midiendo la densidad (tanto la aparente como la de compactación), el índice Carr (índice de compactabilidad), la fluidez (velocidad de flujo a través de un orificio se mide como la masa por tiempo que fluye desde un embudo, método USP) y la PPS. El resumen de los resultados se muestra en la Tabla 4.
Tabla 4.
- Lote
- Densidad % Índice Carr Flujo de masa g/s (100 g) PPS %
- No compactada
- Compactada Ø 10 mm g/s Ø 15 mm g/s Ø 20 mm g/s Ø 30 mm g/s T = 0 24 h/ temp. amb; vial cerrado 24 h/ temp. amb; vial abierto 72 h/ temp. amb; vial cerrado 72 h/ temp. amb; vial abierto
- Muestra de referenciaA
- 0.657 0.781 15.88 7.1 / / / 0.96 1.51 2.69 / /
- Celulosa microcristalina C3
- 0.438 0.561 21.93 Sin flujo Sin flujo Sin flujo 20.8 3.68 4.05 4.04 / /
- Celulosa microcristalina B2
- 0.423 0.500 15.40 10.4 / / / 1.09 1.59 2.12 / /
- Trehalosa G
- 0.757 0.892 15.13 5.9 / / / 6.45 6.7 2 6.52 / /
- Lactosa monohidratada
- 0.549 0.632 13.13 7.1 / / / 0.43 0.71 0.87 / /
- L-Prolina
- 0.512 0.581 11.88 4.5 / / / 0.43 / / 0.52 0.97
- Calcio bibásico
- 0.694 0.806 13.90 9.1 / / / 0.70 / / 0.89 1.25
- Isomalt
- 0.434 0.500 13.20 5.5 / / / 2.55 / / 2.57 2.84
- Lactosa Anhidra
- 0.769 0.833 7.68 4.34 / / / 0.43 / / 0.51 0.86
- Celulosa microcristalina A1
- 0.434 0.515 15.73 4.34 / / / 3.89 3.92 3.96 / /
- Inositol
- 0.609 0.781 22.02 6.66 / / / 0.61 / / 0.45 0.93
- Mezclas de celulosa microcristalina B2 +C3 (1:1)
- 0.442 0.549 19.49 Sin flujo 5.88 / / 2.72 2.8 2.91 / /
- Celulosa microcristalina A1 + C3 (1:1)
- 0.454 0.568 20.07 Sin flujo 14.28 / / 3.36 4.17 4.17 / /
- Celulosa microcristalina C3 + trehalosa G (1:1)
- 0.561 0.724 22.51 Sin flujo 8.33 / / 2.78 5.64 5.86 / /
- Celulosa microcristalina C3 + L-prolina (1:1)
- 0.515 0.649 20.65 Sin flujo 12.5 / / 2.39 2.19 2.18 / /
- Celulosa microcristalina C3 + lactosa anhidra (1:1)
- 0.555 0.684 18.86 Sin flujo 3.33 / / 2.07 2.27 2.15 / /
15
E11788223
13-10-2014
- Lote
- Densidad % Índice Carr Flujo de masa g/s (100 g) PPS %
- No compactada
- Compactada Ø 10 mm g/s Ø 15 mm g/s Ø 20 mm g/s Ø 30 mm g/s T = 0 24 h/ temp. amb; vial cerrado 24 h/ temp. amb; vial abierto 72 h/ temp. amb; vial cerrado 72 h/ temp. amb; vial abierto
- Celulosa microcristalina C3 + lactosa monohidratada (1:1)
- 0.521 0.657 20.70 Sin flujo 10.0 / / 1.94 2.18 2.36 / /
- Celulosa microcristalina C3 + calcio bibásico (1:1)
- 0.561 0.704 20.31 Sin flujo 10.5 / / 2.1 2.5 2.65 /
- Celulosa microcristalina C3 + Isomalt (1:1)
- 0.510 0.609 16.26 Sin flujo 12.5 / / 3.38 3.37 3.4 / /
- Celulosa microcristalina C3 + Inositol (1:1)
- 0.531 0.675 21.33 Sin flujo 6.66 / / 2.29 / / 2.06 2.27
- A Muestra de referencia: pancreolipasa (90%), croscarmelosa sódica (3.0%), aceite de ricino hidrogenado (1.0%), dióxido de silicio coloidal (0.5%), celulosa microcristalina (5%) (Avicel® PH101); estearato de magnesio (0.5%)
Tabla 5. Tipos de celulosas microcristalinas
- imagen14
- Tamaño medio nominal de partícula (µm) Análisis del tamaño de partícula: PPS
- imagen15
- Tamaño de malla Cantidad retenida %
- 1Celulosa microcristalina A
- 160 38 ≤1 <5%
- 94
- ≤ 50
- imagen16
-
imagen17 300 ≤ 70
- 2Celulosa microcristalina B
- 180 60 ≥ 10.0 <5%
- 100
- ≥ 50
- 3Celulosa microcristalina C
- 50 60 ≤ 1 <5%
- 200
- ≤ 30
La celulosa cristalina A se comercializa como Vivapure®12; la celulosa cristalina B se comercializa como Avicel® 5 LM200; la celulosa cristalina C se comercializa como Avicel® PH101.
De la tabla 4 anterior se evidencia que la celulosa microcristalina C (contenido de humedad menor o igual de 5%, tamaño medio nominal de partícula de 50 µm, tamaño de malla 60: cantidad retenida ≤1.0%, tamaño de malla 200: cantidad retenida ≤ 30.0%) tiene un flujo de masa bajo que es una indicación de problemas críticos durante el
10 proceso de compresión directa. Para evitar dichos problemas con portadores que tienen baja fluidez, se debería llevar a cabo un paso de tratamiento adicional (como granulación húmeda) para aumentar el flujo de masa. Sin embargo, cualquiera de dichos pasos adicionales son perjudiciales para la actividad enzimática de la formulación de pancreolipasa y por consiguiente se deben evitar para reducir el riesgo de degradación.
15 Ejemplo 3. Mediciones de la dureza de los comprimidos de las mezclas de pancreolipasa - portador
La materia prima pancreolipasa (p. ej, recibida de Nordmark) se mezcla con diferentes portadores para formar las siete mezclas distintas: mezcla 1: pancreolipasa; mezcla 2: pancreolipasa y celulosa microcristalina B; mezcla 3: pancreolipasa y trehalosa; mezcla 4: pancreolipasa e isomalt; mezcla 5: pancreolipasa y calcio bibásico; mezcla 6:
16
E11788223
13-10-2014
Tabla 12. Estabilidad de microcomprimidos a granel de pancreolipasa diluida con recubrimiento entérico (µC); condiciones de almacenamiento: 40 °C + 75% de humedad relativa
- imagen21
- Actividad de lipasa unidades USP/mg
- Lote
- Tiempo 0 Tiempo 3 mo Dif. tiempo
- µC1 (portador: celulosa microcristalina A)
- 11.5 11.2 97
- µC2 (portador: celulosa microcristalina A y trehalosa)
- 11.7 11.7 100
- µC3 (portador: celulosa microcristalina B y trehalosa)
- 11.5 11.4 99
Tabla 13. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC1 (portador: celulosa microcristalina A); condiciones de almacenamiento: 25 °C, 60% de humedad relativa
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Aspecto
- Perlas livianas pequeñas marrones corresp corresp corresp corresp
- Actividad de lipasa (unidades USP/cps)
- 90-110% de lo declarado en la rotulación 735 761 754 774
- 675-825 unidades USP/cps
- % declarado en la rotulación
- 98 101 101 103
- Dff T0 (%)
- 104 103 105
- Actividad de proteasa (unidades USP/cps)
- 1250-3850 unidades USP/cps 2015 2145 2145 2210
- Actividad de amilasa (unidades USP/cps)
- 1600-6575 unidades USP/cps 2600 2665 2665 2795
- Ácido ftálico (%)
- NMT 1.4% 0.1 0.1 0.1 0.1
- PPS(%)
- NMT 5.0% 2.4 0.5 0.1 0.3
- Disolución (%)
- NLT 75% 30 min 84% (RSD 3.6) 87% (RSD 2.6) 85% (RSD 2.1) 83% (RSD 3.0)
- Disolución (%) x 1.125
- 95% (RSD 2.9) 98% (RSD 2.2) 96% (RSD 1.5) 94% (RSD 3.0)
- Peso n = 10 (mg)
-
imagen22 65 65 65 65
Tabla 14. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC1 (portador: celulosa microcristalina A); condiciones de almacenamiento: 40 °C, 75% de humedad relativa
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Aspecto
- Perlas livianas pequeñas marrones corresp corresp corresp corresp
- Actividad de lipasa (unidades USP/cps)
- 90-110% de lo declarado en la rotulación 735 754 754 754
- 675-825 unidades USP/cps
- % declarado en la rotulación
- 98 101 101 101
- Dff T0 (%)
- 103 103 103
- Actividad de proteasa (unidades
- 1250-3850 unidades USP/cps 2015 2080 2015 2015
- USP/cps
-
imagen23
20
E11788223
13-10-2014
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Actividad de amilasa (unidades USP/cps)
- 1600-6575 unidades USP/cps 2600 2665 2600 2795
- Ácido ftálico (%)
- NMT 1.4% 0.1 0.1 0.1 0.1
- PPS(%)
- NMT 5.0% 2.4 0.4 0.1 0.2
- Disolución (%)
- NLT 75% 30 min 84% (RSD 3.6) 84% (RSD 2.9) 83% (RSD 2.2) 82% RD 1.8)
- Disolución (%) x 1.125
-
imagen24 95% (RSD 2.9) 94% (RSD 2.2) 96% (RSD 2.3) 93% (RSD 1.8)
- Peso n = 10 (mg)
-
imagen25 65 65 65 65
Tabla 15. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC2 (portador: celulosa microcristalina A y trehalosa); condiciones de almacenamiento: 25 °C, 76% de humedad relativa
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Aspecto
- Perlas livianas pequeñas marrones corresp corresp corresp corresp
- Actividad de lipasa (unidades USP/cps)
- 90-110% de lo declarado en la rotulación 736 755 762 755
- 675-825 unidades USP/cps
-
imagen26 imagen27 imagen28
- % declarado en la rotulación
- 98 101 102 101
- Dff T0 (%)
-
imagen29 103 104 103
- Actividad de proteasa (unidades USP/cps)
- 1250-3850 unidades USP/cps 1984 2048 1984 2112
- Actividad de amilasa (unidades USP/cps)
- 1600-6575 U USP/cps 2496 2688 2880 2816
- Ácido ftálico (%)
- NMT 1.4% 0.1 0.1 0.1 0.1
- PPS(%)
- NMT 5.0% 1.6 0.2 0.2 0.3
- Disolución (%)
- NLT 75% 30 min 84% (RSD 2.0) 91% (RSD 3.6) 87% (RSD 2.4) 86% RD 12.2)
- Disolución (%) x 1.125
-
imagen30 94% (RSD 2.3) 103% (RSD 3.6) 98% (RSD 2.5) 96% (RSD 1.7)
- Peso n = 10 (mg)
-
imagen31 64 64 64 64
Tabla 16. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC2 (portador: celulosa microcristalina A y trehalosa); condiciones de almacenamiento: 40 °C, 75% de humedad relativa
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Aspecto
- Perlas livianas pequeñas marrones corresp corresp corresp corresp
- Actividad de lipasa (unidades USP/cps)
- 90-110% de lo declarado en la rotulación 736 755 781 742
- imagen32
-
675-825 unidades USP/cps
imagen33 imagen34 imagen35
- imagen36
- % declarado en la rotulación 98 101 104 199
- imagen37
-
Dff T0 (%)
imagen38 103 106 101
- Actividad de proteasa (unidades USP/cps)
- 1250-3850 unidades USP/cps 1984 2240 2048 1984
21
E11788223
13-10-2014
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Actividad de amilasa (unidades USP/cps)
- 1600-6575 unidades USP/cps 2496 2688 2880 2688
- Ácido ftálico (%)
- NMT 1.4% 0.1 0.1 0.1 0.1
- PPS(%)
- NMT 5.0% 1.6 0.5 0.2 0.3
- Disolución (%)
- NLT 75% 30 min 84% (RSD 2.0) 91% (RSD 2.6) 87% (RSD 3.7) 84% RD 1.4)
- Disolución (%) x 1.125
-
imagen39 94% (RSD 2.3) 103% (RSD 2.7) 98% (RSD 4.0) 94% (RSD 1.7)
- Peso n = 10 (mg)
-
imagen40 64 64 64 64
Tabla 17. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC3 (portador: celulosa microcristalina B y trehalosa); condiciones de almacenamiento: 25 °C, 60% de humedad relativa
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Aspecto
- Perlas livianas pequeñas marrones corresp corresp corresp corresp
- Actividad de lipasa (unidades USP/cps)
- 90-110% de lo declarado en la rotulación 746 770 779 792
- 675-825 unidades USP/cps
-
imagen41 imagen42 imagen43
- % declarado en la rotulación
- 99 104 104 106
- Dff T0 (%)
-
imagen44 104 104 106
- Actividad de proteasa (unidades USP/cps)
- 1250-3850 unidades USP/cps 1980 2112 2112 2112
- Actividad de amilasa (unidades USP/cps)
- 1600-6575 unidades USP/cps 2640 2838 2772 2838
- Ácido Ftáltico (%)
- NMT 1.4% 0.1 0.1 0.1 0.1
- PPS(%)
- NMT 5.0% 1.6 0.5 0.2 0.3
- Disolución (%)
- NLT 75% 30 min 87% (RSD 2.4) 91% (RSD 2.6) 89% (RSD 1.4) 91% RD 3.4)
- Disolución (%) x 1.125
-
imagen45 98% (RSD 2.1) 102% (RSD 2.7) 100% (RSD 1.2) 103% (RSD 3.4)
- Peso n = 10 (mg)
-
imagen46 66 66 66 66
Tabla 18. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC3 (portador: celulosa microcristalina B y trehalosa); condiciones de almacenamiento: 40 °C, 75% de humedad relativa
- Prueba
- Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
- Aspecto
- Perlas livianas pequeñas marrones corresp corresp corresp corresp
- Actividad de lipasa (unidades USP/cps)
- 90-110% de lo declarado en la rotulación 746 766 766 766
- imagen47
-
675-825 unidades USP/cps
imagen48 imagen49 imagen50
- imagen51
- % declarado en la rotulación 99 102 102 102
- imagen52
-
Dif T0 (%)
imagen53 103 103 103
- Actividad de proteasa (unidades USP/cps)
- 1250-3850 unidades USP/cps 1980 1980 2046 2046
22
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38903710P | 2010-10-01 | 2010-10-01 | |
US389037P | 2010-10-01 | ||
PCT/IB2011/002419 WO2012042372A1 (en) | 2010-10-01 | 2011-09-30 | Enteric coated, low- strength pancrelipase formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2515715T3 true ES2515715T3 (es) | 2014-10-30 |
ES2515715T5 ES2515715T5 (es) | 2021-06-22 |
Family
ID=45044628
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11788223T Active ES2515715T5 (es) | 2010-10-01 | 2011-09-30 | Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico |
ES14176579.2T Active ES2657673T3 (es) | 2010-10-01 | 2011-09-30 | Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14176579.2T Active ES2657673T3 (es) | 2010-10-01 | 2011-09-30 | Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad |
Country Status (26)
Country | Link |
---|---|
US (2) | US11364205B2 (es) |
EP (2) | EP2621476B8 (es) |
JP (2) | JP6043929B2 (es) |
KR (2) | KR101968457B1 (es) |
CN (2) | CN108187033A (es) |
AR (1) | AR093181A1 (es) |
AU (2) | AU2011309763B2 (es) |
BR (1) | BR112013007640A2 (es) |
CA (1) | CA2812862C (es) |
CL (1) | CL2011002432A1 (es) |
CO (1) | CO6700848A2 (es) |
DK (1) | DK2621476T4 (es) |
EA (3) | EA030450B1 (es) |
ES (2) | ES2515715T5 (es) |
HR (1) | HRP20140995T1 (es) |
IL (1) | IL225504A (es) |
MX (1) | MX348118B (es) |
PL (1) | PL2621476T5 (es) |
PT (1) | PT2621476E (es) |
RS (1) | RS53587B1 (es) |
SA (1) | SA111320804B1 (es) |
SI (1) | SI2621476T1 (es) |
SM (1) | SMT201400149B (es) |
UA (1) | UA111726C2 (es) |
WO (1) | WO2012042372A1 (es) |
ZA (1) | ZA201303087B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
SG186648A1 (en) | 2007-02-20 | 2013-01-30 | Aptalis Pharma Ltd | Stable digestive enzyme compositions |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
PL2318035T3 (pl) | 2008-07-01 | 2019-10-31 | Curemark Llc | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
KR20170005192A (ko) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법 |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
JP6043929B2 (ja) | 2010-10-01 | 2016-12-14 | アラガン ファーマシューティカルズ インターナショナル リミテッド | 腸溶コーティングされた低力価パンクレリパーゼ製剤 |
BR112013027034A8 (pt) | 2011-04-21 | 2018-01-02 | Curemark Llc | "compostos para o tratamento de transtornos neuropsiquiátricos." |
EP2987499B1 (en) | 2011-08-08 | 2019-05-08 | Allergan Pharmaceuticals International Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
US10350278B2 (en) * | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
AU2014229330B2 (en) | 2013-03-15 | 2018-08-09 | Allergan Pharmaceuticals International Limited | Composition containing digestive enzymes and nutrients suitable for enteral administration |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
JP2016537387A (ja) * | 2013-08-09 | 2016-12-01 | アラガン ファーマシューティカルズ インターナショナル リミテッド | 経腸投与に適した消化酵素組成物 |
CN106659773A (zh) * | 2013-11-05 | 2017-05-10 | 阿勒根制药国际有限公司 | 高效的胰酶药物组合物 |
JP6442659B1 (ja) * | 2017-12-28 | 2018-12-26 | 株式会社フクハラ | 細菌増殖警報器付き除菌フィルタ |
WO2020257802A1 (en) * | 2019-06-21 | 2020-12-24 | Das Aditya | Spray dried oral pharmaceutical compositions for enteric hepatic or intestinal delivery |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2751330A (en) | 1952-08-27 | 1956-06-19 | Armour & Co | Use of a salt in the extraction slurry in recovering proteolytic enzymes from pancreas gland material |
FR1484458A (es) | 1965-06-25 | 1967-09-15 | ||
GB1342409A (en) | 1970-07-23 | 1974-01-03 | Ciba Geigy Ag | Flowable pancreatin preparation of low microorgan ism content and a process for its manufacture |
DE2460334C3 (de) | 1974-12-20 | 1979-09-06 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Gewinnung von Insulin und Pankreatin aus Schweinepankreas |
GB1509866A (en) | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
US4237229A (en) | 1975-06-10 | 1980-12-02 | W. R. Grace & Co. | Immobilization of biological material with polyurethane polymers |
GB1590432A (en) † | 1976-07-07 | 1981-06-03 | Novo Industri As | Process for the production of an enzyme granulate and the enzyme granuate thus produced |
JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
DE2923279C2 (de) | 1979-06-08 | 1987-07-09 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel |
JPS5885159A (ja) | 1981-11-17 | 1983-05-21 | Furointo Sangyo Kk | 溶出試験装置 |
EP0115023B1 (de) | 1982-12-30 | 1988-07-27 | Nordmark Arzneimittel GmbH | Verfahren zur Gewinnung von Pankreatin |
US4447412A (en) | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
DE3445301A1 (de) | 1984-12-12 | 1986-06-12 | Hoechst Ag, 6230 Frankfurt | Pankreasenzympraeparate und verfahren zu deren herstellung |
DE3689727T2 (de) | 1985-12-27 | 1994-07-07 | Showa Denko Kk | Granulierungsverfahren für enzyme. |
US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
HU207452B (en) | 1986-03-21 | 1993-04-28 | Eurasiam Lab | Method for producing therapeutical preparations containing active ingredient having biologicallu active protein structure |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
FR2603804B1 (fr) | 1986-09-17 | 1989-10-27 | Jouveinal Sa | Lipases et extraits lipasiques, leur procede de preparation et leur application en therapeutique |
IT1205716B (it) | 1987-01-21 | 1989-03-31 | Samil Spa | Procedimento per la preparazione di microsfere gastroresistenti ed enterosolubili di enzima digestivo e preparato faramceutico a microsfere cosi' prodotto |
DK435687D0 (da) † | 1987-08-21 | 1987-08-21 | Novo Industri As | Enzymholdigt granulat og fremgangsmaade til fremstilling deraf |
US5733763A (en) † | 1988-08-19 | 1998-03-31 | Novo Nordisk A/S | Enzyme granulate formed of an enzyme-containing core and an enzyme-containing shell |
DK78089D0 (da) † | 1989-02-20 | 1989-02-20 | Novo Industri As | Detergentholdigt granulat og fremgangsmaade til fremstilling deraf |
DK78189D0 (da) † | 1989-02-20 | 1989-02-20 | Novo Industri As | Enzymholdigt granulat og fremgangsmaade til fremstilling deraf |
DK306289D0 (da) † | 1989-06-21 | 1989-06-21 | Novo Nordisk As | Detergentadditiv i granulatform |
DE3927286C2 (de) | 1989-08-18 | 1997-07-24 | Roehm Gmbh | Wäßrige Enzym-Flüssigformulierungen |
CA2030581C (en) | 1989-11-24 | 2000-06-27 | Gunther Atzl | Pancreatin preparations |
IT1246350B (it) | 1990-07-11 | 1994-11-17 | Eurand Int | Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili |
JPH0790565B2 (ja) | 1991-08-06 | 1995-10-04 | 株式会社日本製鋼所 | 樹脂成形プレスのスライド制御方法及びその装置 |
US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
WO1993007859A1 (en) | 1991-10-23 | 1993-04-29 | Warner-Lambert Company | Novel pharmaceutical pellets and process for their production |
SE9200858L (sv) | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Metod för framställning av pellets med fördröjd frisättning |
US5616483A (en) | 1992-06-11 | 1997-04-01 | Aktiebolaget Astra | Genomic DNA sequences encoding human BSSL/CEL |
US5578304A (en) | 1992-06-22 | 1996-11-26 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5460812A (en) † | 1992-06-22 | 1995-10-24 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5260074A (en) | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
DE4227385A1 (de) | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pankreatinmikropellets |
JP3264027B2 (ja) | 1993-02-24 | 2002-03-11 | ソニー株式会社 | 放電セル及びその製造方法 |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
RU94017352A (ru) | 1994-05-11 | 1996-07-27 | Товарищество с ограниченной ответственностью "Инвест" | Способ лечения онкологических больных, перенесших операцию на желудочно-кишечном тракте |
DE4422433A1 (de) † | 1994-06-28 | 1996-01-04 | Cognis Bio Umwelt | Mehrenzymgranulat |
JPH10503739A (ja) | 1994-08-05 | 1998-04-07 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 感湿性物質用容器 |
US5733575A (en) | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
EP0828509B1 (en) | 1995-05-31 | 2005-01-26 | Medzyme N.V. | Composition to improve digestibility and utilisation of nutrients |
US6057139A (en) * | 1995-06-29 | 2000-05-02 | Mcneil-Ppc, Inc. | Preblend of microcrystalline cellulose and lactase for making tablets |
US5665428A (en) | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
US5750104A (en) † | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
DE19622131A1 (de) † | 1996-06-01 | 1997-12-04 | Solvay Enzymes Gmbh & Co Kg | Neue Enzymgranulate |
EP0938657A4 (en) | 1996-06-04 | 1999-10-27 | Euro Celtique Sa | IMPROVEMENTS OF DETECTION SYSTEMS AND METHOD FOR PREDICTING THE RESOLUTION CURVE OF A MEDICINE OF A PHARMACEUTICAL DOSAGE FORM |
JPH1023888A (ja) | 1996-07-10 | 1998-01-27 | Kao Corp | 酵素造粒物の製造方法 |
DE19724845A1 (de) | 1996-08-28 | 1998-03-05 | Solvay Pharm Gmbh | Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen |
US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
GB9623205D0 (en) | 1996-11-07 | 1997-01-08 | Eurand Int | Novel pharmaceutical compositions |
CA2198317C (en) | 1997-02-24 | 2003-01-07 | Mouhsine El Abboudi | Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof |
JPH10295374A (ja) | 1997-04-30 | 1998-11-10 | Amano Pharmaceut Co Ltd | 安定な酵素顆粒の製造法 |
DE19721467A1 (de) | 1997-05-22 | 1998-11-26 | Basf Ag | Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe |
SE9702338D0 (sv) | 1997-06-18 | 1997-06-18 | Astra Ab | An analytical method and industrial process including the same |
ES2137862B1 (es) | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
JP3611456B2 (ja) | 1997-09-30 | 2005-01-19 | 日研化学株式会社 | テオフィリン徐放性錠剤 |
KR19990072826A (ko) | 1998-02-26 | 1999-09-27 | 우재영 | 판크레아틴장용코팅과립의제조방법 |
US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
JPH11315043A (ja) | 1998-04-30 | 1999-11-16 | Lion Corp | ヒドロキシエーテル化合物の製造方法及び洗浄剤組成物 |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US20010024660A1 (en) | 1999-09-29 | 2001-09-27 | Ismat Ullah | Enteric coated pharmaceutical composition and method of manufacturing |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
WO2000025752A1 (en) | 1998-11-02 | 2000-05-11 | Church, Marla, J. | Multiparticulate modified release composition |
ATE376057T1 (de) | 1999-10-01 | 2007-11-15 | Novozymes As | Enzymgranulat |
US20010046493A1 (en) | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
AU2001254730A1 (en) | 2000-03-24 | 2001-10-03 | Societe Des Produits Nestle S.A. | Nutritional composition comprising hydrolysed protein |
AU2001244093A1 (en) | 2000-04-03 | 2001-10-15 | Novozymes A/S | Enzyme tablets for cleaning improvement |
IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
AUPR272901A0 (en) | 2001-01-25 | 2001-02-22 | Gainful Plan Limited | Method of preparing biological materials and preparations produced using same |
DE60124895D1 (de) | 2001-07-26 | 2007-01-11 | Ethypharm Sa | Umgehüllte Allylamine oder Benzylamine enthaltende Granulate, Verfahren zur Herstellung und in der Mundhöhle dispergierbare Tabletten enthaltend die umgehüllten Granulate |
JP4187085B2 (ja) | 2001-08-24 | 2008-11-26 | 三菱電機株式会社 | 車両用乗員保護装置 |
US20040197321A1 (en) * | 2002-03-19 | 2004-10-07 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
CN1156308C (zh) | 2002-04-19 | 2004-07-07 | 北京世诺医药科技有限公司 | 多酶组合胶囊 |
US20040121010A1 (en) | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
WO2004049820A1 (ja) * | 2002-11-29 | 2004-06-17 | Freund Corporation | 水性セラック皮膜剤、その製造方法、該皮膜剤を用いたコーテッド食品、その製造方法、コーテッド医薬品、その製造方法、油性菓子の艶付用組成物、艶付方法、及び艶付油性菓子 |
CA2419572A1 (en) | 2003-02-18 | 2004-08-18 | Axcan Pharma Inc. | High dosage protease formulation |
US20040213847A1 (en) | 2003-04-23 | 2004-10-28 | Matharu Amol Singh | Delayed release pharmaceutical compositions containing proton pump inhibitors |
WO2005042012A1 (en) | 2003-10-29 | 2005-05-12 | Altus Pharmaceuticals Inc. | Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain |
US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
PT1729797E (pt) | 2004-03-22 | 2008-12-17 | Solvay Pharm Gmbh | Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos |
US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
US20060013807A1 (en) * | 2004-07-13 | 2006-01-19 | Chapello William J | Rapidly disintegrating enzyme-containing solid oral dosage compositions |
US20060198838A1 (en) | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
CN101068565B (zh) | 2004-10-14 | 2010-11-17 | 胞囊纤维化基础治疗公司 | 治疗胰腺功能不全的包含脂酶、蛋白酶和淀粉酶的组合物 |
CN1247106C (zh) * | 2004-11-01 | 2006-03-29 | 广东溢多利生物科技股份有限公司 | 多色微丸型饲用复合酶及其制造方法 |
JP4891549B2 (ja) | 2005-01-19 | 2012-03-07 | 富士フイルム株式会社 | プラスチック成形用金型 |
US20070025977A1 (en) † | 2005-07-21 | 2007-02-01 | Mulberg Andrew E | Method of treating steatorrhea in infants |
KR101199196B1 (ko) | 2005-07-25 | 2012-11-07 | (주)다산메디켐 | 구형의 판크레아틴 과립의 제조방법 |
AU2006274835B2 (en) | 2005-07-29 | 2012-05-24 | Abbott Laboratories Gmbh | Processes for the manufacture of sterilized pancreatin powder |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
ATE457719T2 (de) | 2005-08-15 | 2010-03-15 | Solvay Pharm Gmbh | Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel |
JP5284092B2 (ja) | 2005-08-15 | 2013-09-11 | アボット ラボラトリーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腸溶コーティングに適したパンクレアチンマイクロペレットコア |
WO2007053619A2 (en) | 2005-11-01 | 2007-05-10 | Bio-Cat, Inc. | A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
US20070141151A1 (en) | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
JP5053865B2 (ja) † | 2005-12-28 | 2012-10-24 | 武田薬品工業株式会社 | 口腔内崩壊性固形製剤の製造法 |
SG169334A1 (en) | 2006-01-21 | 2011-03-30 | Abbott Gmbh & Co Kg | Dosage form and method for the delivery of drugs of abuse |
JP2009538342A (ja) | 2006-05-26 | 2009-11-05 | ネステク ソシエテ アノニム | トウチ抽出物の使用方法及び栄養組成物 |
EP2051591B1 (en) | 2006-08-07 | 2016-04-20 | Novozymes A/S | Enzyme granules for animal feed |
KR100804096B1 (ko) † | 2006-08-31 | 2008-02-18 | (주)아모레퍼시픽 | 고농도 계면활성제 계에서도 안정한 효소 캡슐 제제를포함하는 피부 세정용 조성물 및 그 제조방법 |
US9011843B2 (en) * | 2006-12-14 | 2015-04-21 | Master Supplements, Inc. | Formulations including monovalent alginate to enhance effectiveness of administered digestive enzymes |
US8066986B2 (en) | 2007-02-01 | 2011-11-29 | Master Supplements, Inc. | Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms |
US20080199448A1 (en) | 2007-02-16 | 2008-08-21 | Ross Mairi R | Enzyme composition for improving food digestion |
RU2445952C2 (ru) | 2007-02-20 | 2012-03-27 | Юранд Фармасьютикалз Лимитед | Стабильные композиции пищеварительных ферментов |
SG186648A1 (en) | 2007-02-20 | 2013-01-30 | Aptalis Pharma Ltd | Stable digestive enzyme compositions |
US20090117180A1 (en) † | 2007-02-20 | 2009-05-07 | Giovanni Ortenzi | Stable digestive enzyme compositions |
AU2008239737A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
CN101440361A (zh) * | 2007-11-22 | 2009-05-27 | 珠海百康生物技术有限公司 | 一种制备稳定的包被颗粒酶的方法 |
KR20100101106A (ko) | 2008-01-03 | 2010-09-16 | 애보트 프러덕츠 게엠베하 | 정제 미생물 리파제 과립들을 포함하는 약학 조성물 및 소화 장애들의 예방 또는 치료방법 |
CN101249081A (zh) | 2008-02-15 | 2008-08-27 | 南京大渊美容保健有限公司 | 口服控释给药药片 |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
EP2328609A1 (en) | 2008-08-26 | 2011-06-08 | Cystic Fibrosis Foundation Therapeutics, Inc. | Rapidly disintegrating tablets comprising lipase, amylase, and protease |
CN101430279A (zh) | 2008-10-27 | 2009-05-13 | 江南大学 | 荧光分光光度法筛选催化非水相体系转酯化反应用酶的方法 |
CN101623269A (zh) * | 2009-08-04 | 2010-01-13 | 南京大渊美容保健有限公司 | 口服缓释给药的颗粒 |
US8784884B2 (en) | 2009-09-17 | 2014-07-22 | Stephen Perrett | Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency |
JP2011093845A (ja) | 2009-10-29 | 2011-05-12 | 宏之 ▲今▼西 | 胃瘻用注入剤及びその注入装置 |
WO2011072069A2 (en) † | 2009-12-08 | 2011-06-16 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for extended release of polypeptides |
RU2012142134A (ru) | 2010-03-19 | 2014-04-27 | Апталис Фарма Кэнэда Инк. | Желудочно-резистентные ферментные фармацевтические композиции |
JP5876472B2 (ja) | 2010-04-14 | 2016-03-02 | ダウ グローバル テクノロジーズ エルエルシー | フロス及び非フロスコーティング用の分配装置 |
GB201006178D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
TW201210517A (en) | 2010-08-06 | 2012-03-16 | Aptalis Pharma Ltd | Predigested nutritional formula |
AR082943A1 (es) | 2010-08-06 | 2013-01-23 | Aptalis Pharma Ltd | Formula nutricional predigerida |
JP6043929B2 (ja) | 2010-10-01 | 2016-12-14 | アラガン ファーマシューティカルズ インターナショナル リミテッド | 腸溶コーティングされた低力価パンクレリパーゼ製剤 |
TW201216951A (en) | 2010-10-21 | 2012-05-01 | Aptalis Pharma Ltd | Oral dosing device for administration of medication |
JP6166714B2 (ja) | 2011-03-27 | 2017-07-19 | セルレシン テクノロジーズ, エルエルシー | シクロデキストリン組成物、物品、及び方法 |
EP2987499B1 (en) | 2011-08-08 | 2019-05-08 | Allergan Pharmaceuticals International Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
CN103060296B (zh) | 2012-12-30 | 2014-05-21 | 青岛九龙生物医药有限公司 | 从动物胰脏中提取胰蛋白酶的方法 |
AU2014229330B2 (en) | 2013-03-15 | 2018-08-09 | Allergan Pharmaceuticals International Limited | Composition containing digestive enzymes and nutrients suitable for enteral administration |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
MX2016000794A (es) | 2013-07-22 | 2016-12-02 | Allergan Pharmaceuticals Int Ltd | Composiciones farmaceuticas de pancreatina de potencia alta. |
JP2016537387A (ja) | 2013-08-09 | 2016-12-01 | アラガン ファーマシューティカルズ インターナショナル リミテッド | 経腸投与に適した消化酵素組成物 |
CN106659773A (zh) | 2013-11-05 | 2017-05-10 | 阿勒根制药国际有限公司 | 高效的胰酶药物组合物 |
EP3035780A1 (de) | 2014-12-18 | 2016-06-22 | Siemens Aktiengesellschaft | Kühlkörper |
CN204811577U (zh) † | 2015-07-09 | 2015-12-02 | 佛山市南海中宇渔具有限公司 | 渔轮及其线壳 |
-
2011
- 2011-09-30 JP JP2013530811A patent/JP6043929B2/ja not_active Expired - Fee Related
- 2011-09-30 ES ES11788223T patent/ES2515715T5/es active Active
- 2011-09-30 WO PCT/IB2011/002419 patent/WO2012042372A1/en active Application Filing
- 2011-09-30 RS RSP20140580 patent/RS53587B1/en unknown
- 2011-09-30 AR ARP110103646A patent/AR093181A1/es unknown
- 2011-09-30 AU AU2011309763A patent/AU2011309763B2/en not_active Ceased
- 2011-09-30 PT PT117882233T patent/PT2621476E/pt unknown
- 2011-09-30 MX MX2013003627A patent/MX348118B/es active IP Right Grant
- 2011-09-30 CN CN201810041386.9A patent/CN108187033A/zh active Pending
- 2011-09-30 KR KR1020187021606A patent/KR101968457B1/ko active IP Right Grant
- 2011-09-30 EP EP11788223.3A patent/EP2621476B8/en active Active
- 2011-09-30 ES ES14176579.2T patent/ES2657673T3/es active Active
- 2011-09-30 CA CA2812862A patent/CA2812862C/en active Active
- 2011-09-30 EA EA201590836A patent/EA030450B1/ru not_active IP Right Cessation
- 2011-09-30 CL CL2011002432A patent/CL2011002432A1/es unknown
- 2011-09-30 BR BR112013007640A patent/BR112013007640A2/pt not_active Application Discontinuation
- 2011-09-30 EA EA201590835A patent/EA030449B1/ru not_active IP Right Cessation
- 2011-09-30 SI SI201130239T patent/SI2621476T1/sl unknown
- 2011-09-30 EP EP14176579.2A patent/EP2818160B1/en not_active Revoked
- 2011-09-30 DK DK11788223.3T patent/DK2621476T4/da active
- 2011-09-30 PL PL11788223T patent/PL2621476T5/pl unknown
- 2011-09-30 EA EA201390409A patent/EA029101B1/ru not_active IP Right Cessation
- 2011-09-30 UA UAA201303847A patent/UA111726C2/uk unknown
- 2011-09-30 CN CN201180055719XA patent/CN103221036A/zh active Pending
- 2011-09-30 KR KR1020137010970A patent/KR20140019292A/ko not_active Application Discontinuation
- 2011-10-01 SA SA111320804A patent/SA111320804B1/ar unknown
- 2011-10-03 US US13/251,926 patent/US11364205B2/en active Active
-
2013
- 2013-04-02 IL IL225504A patent/IL225504A/en active IP Right Grant
- 2013-04-03 CO CO13066300A patent/CO6700848A2/es unknown
- 2013-04-26 ZA ZA2013/03087A patent/ZA201303087B/en unknown
-
2014
- 2014-10-16 HR HRP20140995AT patent/HRP20140995T1/hr unknown
- 2014-10-16 SM SM201400149T patent/SMT201400149B/xx unknown
-
2015
- 2015-10-15 AU AU2015243026A patent/AU2015243026B2/en not_active Ceased
-
2016
- 2016-10-05 JP JP2016196831A patent/JP6383394B2/ja not_active Expired - Fee Related
-
2022
- 2022-05-23 US US17/750,648 patent/US20220280433A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2515715T3 (es) | Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico | |
JP6937086B2 (ja) | ブルトン型チロシンキナーゼ阻害剤の結晶形態 | |
AU2010231701B2 (en) | Orally disintegrating coated tablet | |
JP6220485B2 (ja) | コロイドビスマスペクチンを含有する分散製剤及びその製造方法 | |
US20220218602A1 (en) | Oral pharmaceutical composition | |
JP2017523206A (ja) | ブルトン型チロシンキナーゼ阻害剤の新規製剤 | |
RU2600831C2 (ru) | Перорально вводимая фармацевтическая композиция | |
WO2006123678A1 (ja) | ドロキシドパを含有する安定な錠剤 | |
KR20200058496A (ko) | 니라파립 제제 | |
US10881610B2 (en) | Orally disintegrating tablet | |
CN109843269A (zh) | 来那度胺的口服用片剂组合物 | |
JP2012508230A (ja) | ロスバスタチンカルシウム組成物の取得方法及び得られた産物 | |
JP2007153887A (ja) | アンブロキソール口腔内速崩性錠剤 | |
CN101330919B (zh) | 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物 | |
WO2014157264A1 (ja) | 口腔内崩壊性フィルムコーティング錠 | |
CN103282051A (zh) | 口腔内崩解片剂 | |
CN102106809B (zh) | 一种氯吡格雷的固体制剂及其制备方法 | |
ES2949817T3 (es) | Composición farmacéutica que contiene tosilato de sorafenib cristalino | |
JP5822758B2 (ja) | 速溶性防湿フィルムコーティング製剤及びその製造方法 | |
CN105534929A (zh) | 曲格列汀药物组合物 | |
CN108159053A (zh) | 一种含有头孢妥仑匹酯的药物组合物 | |
JP6676816B1 (ja) | L−システイン配合ビタミンc高含有圧縮成形製剤 | |
JPWO2014188729A1 (ja) | 経口用組成物 | |
CN109200020A (zh) | 一种埃索美拉唑镁的药物组合物 | |
Udaya Kiran et al. | Annals of Drug discovery and Biomedical Research |